Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MRG003 With or Without Pucotenlimab in Recurrent or Metastatic Salivary Gland Cancer
NCT07464366Phase 2Recruiting
- Start
- Mar 2026
- Primary completion
- May 2028
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
A Phase 2 trial of becotatug vedotin in salivary gland cancer (SGC). Started Mar 2026; status: recruiting.
02
Drugs
becotatug vedotin
03
Conditions
salivary gland cancer (SGC)
Beyond the preview
Go deeper on NCT07464366.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07464366.